Back to Stocks

PAHC

PHIBRO ANIMAL HEALTH CORP
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Phibro Animal Health is demonstrating a powerful combination of inorganic growth and operational efficiency. The company reported a 22% increase in net sales for the nine months ended March 31, 2026, reaching $1.12 billion.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the top-line growth, Phibro is operating with a precarious balance sheet and significant regulatory headwinds. The company's net leverage is hovering near its covenant ceilings, and interest expenses have climbed 32% year-over-year to $34.2 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every PAHC filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest 10-Q paints a picture of a company at a strategic crossroads, balancing aggressive growth against rising financial risk. Phibro has successfully scaled its operations through the Zoetis acquisition and is seeing genuine demand for its animal health and mineral nutrition products. The ability to expand margins while growing revenue suggests that the business model is scalable and that the company possesses significant pricing power in its niche markets. However, the cost of this growth is a stretched balance sheet and a heightened sensitivity to external shocks. The trade-off for investors is clear: the potential for double-digit earnings growth is offset by the risk of covenant breaches and regulatory setbacks. The upcoming transition period for Brazilian product labels and the outcome of the FDA's review of carbadox will be critical inflection points that determine whether Phibro's current momentum is sustainable or a temporary peak.

Selected Quarter

Core Takeaway

The company is successfully integrating a major acquisition to drive top-line growth, but high debt levels and regulatory threats to key products create a volatile risk profile.

Investor Lens

The balance between aggressive inorganic growth and the ability to service debt while navigating geopolitical instability in Israel.

Watch Next

FDA ruling on Mecadox (carbadox) and the outcome of the 180-day transition period for virginiamycin in Brazil.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.23Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 6

Net income increased significantly to $78 million for the nine months ended March 31, 2026.

earnings beat
80%
bullishMay 6

Adjusted EBITDA margin expanded to 17.0% from 14.6% year-over-year.

margin expansion
70%
neutralMay 6

Increased revolving credit facility capacity to $435 million to enhance operating flexibility.

debt restructure
50%
bearishMay 6

Facing potential FDA withdrawal of Mecadox and Brazilian bans on virginiamycin.

regulatory action
60%
bullishMay 6

Net income increased significantly to $78 million for the nine months ended March 31, 2026.

earnings beat
80%
bullishMay 6

Adjusted EBITDA margin expanded to 17.0% from 14.6% year-over-year.

margin expansion
70%
neutralMay 6

Increased revolving credit facility capacity to $435 million to enhance operating flexibility.

debt restructure
50%
bearishMay 6

Facing potential FDA withdrawal of Mecadox and Brazilian bans on virginiamycin.

regulatory action
60%
bullishMay 6

Net income increased significantly to $78 million for the nine months ended March 31, 2026.

earnings beat
80%
bullishMay 6

Adjusted EBITDA margin expanded to 17.0% from 14.6% year-over-year.

margin expansion
70%
neutralMay 6

Increased revolving credit facility capacity to $435 million to enhance operating flexibility.

debt restructure
50%
bearishMay 6

Facing potential FDA withdrawal of Mecadox and Brazilian bans on virginiamycin.

regulatory action
60%
bullishMay 6

Net income increased significantly to $78 million for the nine months ended March 31, 2026.

earnings beat
80%
bullishMay 6

Adjusted EBITDA margin expanded to 17.0% from 14.6% year-over-year.

margin expansion
70%
neutralMay 6

Increased revolving credit facility capacity to $435 million to enhance operating flexibility.

debt restructure
50%
bearishMay 6

Facing potential FDA withdrawal of Mecadox and Brazilian bans on virginiamycin.

regulatory action
60%
bullishMay 6

Net income increased significantly to $78 million for the nine months ended March 31, 2026.

earnings beat
80%
bullishMay 6

Adjusted EBITDA margin expanded to 17.0% from 14.6% year-over-year.

margin expansion
70%
neutralMay 6

Increased revolving credit facility capacity to $435 million to enhance operating flexibility.

debt restructure
50%
bearishMay 6

Facing potential FDA withdrawal of Mecadox and Brazilian bans on virginiamycin.

regulatory action
60%
bullishMay 6

Net income increased significantly to $78 million for the nine months ended March 31, 2026.

earnings beat
80%
bullishMay 6

Adjusted EBITDA margin expanded to 17.0% from 14.6% year-over-year.

margin expansion
70%
neutralMay 6

Increased revolving credit facility capacity to $435 million to enhance operating flexibility.

debt restructure
50%
bearishMay 6

Facing potential FDA withdrawal of Mecadox and Brazilian bans on virginiamycin.

regulatory action
60%
bullishMay 6

Net income increased significantly to $78 million for the nine months ended March 31, 2026.

earnings beat
80%
bullishMay 6

Adjusted EBITDA margin expanded to 17.0% from 14.6% year-over-year.

margin expansion
70%
neutralMay 6

Increased revolving credit facility capacity to $435 million to enhance operating flexibility.

debt restructure
50%
bearishMay 6

Facing potential FDA withdrawal of Mecadox and Brazilian bans on virginiamycin.

regulatory action
60%

Filing History

10-QMay 6, 2026
Expand Sequence

The latest 10-Q paints a picture of a company at a strategic crossroads, balancing aggressive growth against rising financial risk. Phibro has successfully scaled its operations through the Zoetis acquisition and is seeing genuine demand for its animal health and mineral nutrition products. The ability to expand margins while growing revenue suggests that the business model is scalable and that the company possesses significant pricing power in its niche markets. However, the cost of this growth is a stretched balance sheet and a heightened sensitivity to external shocks. The trade-off for investors is clear: the potential for double-digit earnings growth is offset by the risk of covenant breaches and regulatory setbacks. The upcoming transition period for Brazilian product labels and the outcome of the FDA's review of carbadox will be critical inflection points that determine whether Phibro's current momentum is sustainable or a temporary peak.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.